Novo Nordisk has appointed Jamey Millar, former CEO of Optum Specialty Holdings, as the drug company’s executive vice president of U.S. operations, effective Feb. 5.
In the role, Mr. Millar will oversee Novo Nordisk’s largest sales region, according to Novo Nordisk. The Denmark-based company, which is one of the world’s leading GLP-1 drug manufacturers, announced the executive management change Feb. 3 in its 2025 financial report.
Since 2021, Mr. Millar has served UnitedHealth Group’s OptumRx and Optum Specialty Holdings. Prior to those roles, he worked for GSK and Procter & Gamble for over 20 years, collectively.
The previous executive vice president of U.S. operations, Dave Moore, “decided to leave Novo Nordisk for personal reasons,” Novo Nordisk said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
